# EDGAR Filing Document

**Accession Number:** 0000818479
**File Stem:** 0000818479-23-000013
**Filing Date:** 2023-2
**Character Count:** 57841
**Document Hash:** 237a161805e0c8db839f16e71c8b30f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000818479-23-000013.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0000818479-23-000013

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230228

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DENTSPLY SIRONA Inc.
- **CENTRAL INDEX KEY:** 0000818479
- **STANDARD INDUSTRIAL CLASSIFICATION:** DENTAL EQUIPMENT & SUPPLIES [3843]
- **IRS NUMBER:** 391434669
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-16211
- **FILM NUMBER:** 23678332

**BUSINESS ADDRESS:**
- **STREET 1:** 13320 BALLANTYNE CORPORATE PLACE
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28277-3607
- **BUSINESS PHONE:** 844-546-3722

**MAIL ADDRESS:**
- **STREET 1:** 13320 BALLANTYNE CORPORATE PLACE
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28277-3607

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DENTSPLY INTERNATIONAL INC /DE/
- **DATE OF NAME CHANGE:** 19930630

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENDEX CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version="1.0" ? xray-20230228

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**<u>February 28, 2023</u>**

Date of Report (date of earliest event reported)

**<u>DENTSPLY SIRONA Inc.</u>**

(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| **<u>Delaware</u>** | **<u>0-16211</u>** | **<u>0-16211</u>** | **<u>39-1434669</u>** |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| **<u>13320 Ballantyne Corporate Place,</u>** | **<u>Charlotte</u>** | **<u>North Carolina</u>** | **<u>28277-3607</u>** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

**(<u>844) 848-0137</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | **XRAY** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

□

------

**Item 2.02. - Results of Operations and Financial Condition**

The following information is furnished pursuant to Item 2.02, "Results of Operations and Financial Condition."

On February 28, 2023, DENTSPLY SIRONA Inc. issued the attached press release announcing its net sales and earnings for the fourth quarter and year ended December 31, 2022. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| <u>[99.1](dentsply8kq42022ex991.htm)</u> | DENTSPLY SIRONA Inc. Fourth Quarter and Full Year earnings release issued February 28, 2023, as referenced in Item 2.02. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DENTSPLY SIRONA Inc.

---

| | |
|:---|:---|
| By: | */s/ Glenn G. Coleman* |
|  | Glenn G. Coleman |
|  | Executive Vice President, |
|  | Chief Financial Officer |

---

Date: February 28, 2023

## Exhibit 99.1

![xraya07.jpg](xraya07.jpg)

**Dentsply Sirona Reports Fourth Quarter and Full Year 2022 Results, Provides Full Year 2023 Outlook**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• FY22 net sales decreased (7.3%) to $3,922 million, organic sales decreased (0.5%)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• FY22 GAAP EPS of ($4.41), adjusted EPS of $2.09**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Q4 net sales decreased (10.9%) to $983 million, organic sales decreased (2.6%)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Q4 GAAP EPS of ($0.07), adjusted EPS of $0.46**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• FY23 outlook: net sales of $3.85 - $3.95 billion, organic sales down (1%) to up 2%, <br>adj. EPS range of $1.80 to $2.00** 

**Charlotte, N.C., February 28, 2023** - DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the fourth quarter and full year 2022.

Full year 2022 net sales of $3,922 million decreased (7.3%), compared to $4,231 million for the full year of 2021. Net loss was ($950) million, or ($4.41) per diluted share, compared to income of $411 million, or $1.87 per diluted share for the full year of 2021. Full year 2022 net loss includes a non-cash charges for the impairment of goodwill and intangible assets of $1.1 billion net of tax, which were recorded in the second half of 2022. These charges impacted earnings per diluted share by $5.10. Adjusted earnings per diluted share decreased to $2.09 compared to $2.82 in 2021. Excluding the impact of foreign currency translation, adjusted earnings per share was $2.44. Adjusted EBITDA for the full year of 2022 was $761 million, compared to $978 million in 2021. A reconciliation of Non-GAAP measures (including organic sales, adjusted operating income and margin, adjusted EPS, adjusted EBITDA, and adjusted free cash flow conversion) to GAAP measures is provided below.

Fourth quarter 2022 net sales of $983 million decreased (10.9%), compared to $1,103 million in the fourth quarter of 2021. Net loss was ($15) million, or ($0.07) per diluted share, compared to net income of $119 million, or $0.54 per diluted share in the fourth quarter of 2021. Adjusted earnings per diluted share decreased to $0.46 compared to $0.83 in the fourth quarter of 2021.

"2022 was a challenging year due to both internal and external factors. Despite these challenges, we were pleased to deliver fourth quarter financial results that exceeded the high end of our prior sales and EPS outlook ranges. This represents an important milestone as the Company works to improve performance and rebuild investor and employee confidence," said Simon Campion, Chief Executive Officer. "As we enter a new year, we are intently focused on the changes we are making to our organization, operating model, and cadence, highlighted by the plan we recently announced. Dentsply Sirona is well-positioned in an attractive industry, and we are confident that the combination of industry trends, our robust portfolio, and the actions we are taking now will produce significant long-term value for our stakeholders."

![xraylineonly.jpg](xraylineonly.jpg)

------

**<u>Q4 22 and FY 22 Summary Results (GAAP)</u>**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **(in millions, except per share amount and percentages)** | **Q4 22** | **Q4 21** | **YoY** | **FY 22** | **FY 21** | **YoY** |
| Net Sales | 983 | 1103 | *(10.9%)* | 3922 | 4231 | *(7.3%)* |
| Operating Income/(Loss) | 65 | 172 | *(62.0%)* | (937) | 608 | *NM* |
| *Operating Income/(Loss) %* | *6.6%* | *15.6%* |  | *(23.9%)* | *14.4%* |  |
| Diluted Earnings/(Loss) Per Share | (0.07) | 0.54 | *NM* | (4.41) | 1.87 | *NM* |

---

NM - not meaningful

Percentages are based on actual values and may not recalculate due to rounding.

**<u>Q4 22 and FY 22 Summary Results (Non-GAAP)</u>**<sup>[1]</sup>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **(in millions, except per share amount and percentages)** | **Q4 22** | **Q4 21** | **YoY** | **FY 22** | **FY 21** | **YoY** |
| Net Sales | 983 | 1103 | *(10.9%)* | 3922 | 4231 | *(7.3%)* |
| *Organic Sales Growth %* |  |  | *(2.6%)* |  |  | *(0.5%)* |
| Adj. Operating income | 154 | 235 | *(34.4%)* | 657 | 858 | *(23.4%)* |
| *Adj. Operating income %* | *15.7%* | *21.3%* |  | *16.8%* | *20.3%* |  |
| Adj. EPS | 0.46 | 0.83 | *(44.4%)* | 2.09 | 2.82 | *(25.7%)* |

---

<sup>[1]</sup> Organic sales growth, adjusted operating income, and adjusted EPS are Non-GAAP financial measures which exclude certain items. Please refer to "Non-GAAP Financial Measures" below for a description of these measures and to the tables at the end of this release for a reconciliation between GAAP and Non-GAAP measures.

Percentages are based on actual values and may not recalculate due to rounding.

**<u>Segment Results</u>**

**Technologies & Equipment**

Full year 2022 net sales were $2,318 million, down (7.4%) versus prior year. Foreign currency negatively impacted sales by (7.9%), acquisitions increased sales by 0.1%, while organic sales increased by 0.4% as compared to prior year.

Fourth quarter 2022 net sales were $602 million, down (11.6%) versus prior year. Foreign currency negatively impacted sales by (9.4%), while organic sales decreased by (2.2%) as compared to prior year. The decrease in organic sales was primarily driven by softer implants volume, particularly in China, partially offset by strong aligners growth.

**Consumables**

Full year 2022 net sales were $1,604 million, down (7.1%) versus prior year. Foreign currency negatively impacted sales by (5.2%), divestitures and discontinued products negatively impacted sales by (0.2%), while organic sales decreased by (1.7%) as compared to prior year.

Fourth quarter 2022 net sales were $381 million, down (9.9%) versus prior year. Foreign currency negatively impacted sales by (6.5%), while organic sales decreased by (3.4%) as compared to prior year. The decrease in organic sales was primarily driven by COVID lockdowns in China, partially offset by pricing and contributions from new products.

**<u>Cash Flow and Liquidity</u>**

Operating cash flow in the fourth quarter of 2022 was $142 million, as compared to $222 million in the prior year. Adjusted free cash flow conversion in the quarter was 110%, up from 100% conversion in the prior year fourth quarter. Full year 2022 operating cash flow was $517 million, as compared to $657 million in the prior year. In the fourth quarter, the Company paid $26 million in dividends resulting in a total of $254 million returned to shareholders in 2022. As of December 31, 2022, the Company had $365 million of cash and cash equivalents on its balance sheet.

![xraylineonly.jpg](xraylineonly.jpg)

------

**<u>2023 Outlook</u>**

Going forward, the Company will use adjusted EBITDA margin as its primary profitability metric. Management believes that EBITDA margin is a useful profitability metric because it provides an objective measure of operational performance and excludes certain non-cash charges. The outlook for full year 2023 includes net sales in the range of $3.85 billion to $3.95 billion, down (1%) to up 2% on an organic basis. The outlook assumes foreign currency will be a (100) bps headwind to net sales on a full year basis. Adjusted EBITDA margin is expected to be greater than 18% with adjusted EPS in the range of $1.80 to $2.00.

The Company expects first quarter 2023 organic sales growth of approximately 1% and adjusted EBITDA margin to be greater than 15%.

Further 2023 outlook assumptions are included in the Q4 2022 Earnings Presentation posted on the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. The Company does not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.

**<u>Recent Announcements & Additional Highlights</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• New Executive Team Member** - On February 27, 2023, Dentsply Sirona announced that Richard Rosenzweig has been appointed Senior Vice President, Corporate Development, General Counsel and Secretary. With a 25-year history advising global health care companies, Mr. Rosenzweig joins most recently from AngioDynamics where he led the legal department, including compliance, and served as Secretary to the Board as Senior Vice President, General Counsel & Secretary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Quarterly Cash Dividend Increased** - On February 21, 2023, Dentsply Sirona's Board of Directors approved a 12% increase in the Company's quarterly dividend rate, from the previous rate of $0.125 per share of common stock to $0.14 per share. The dividend is payable on April 14, 2023 to holders of record as of March 31, 2023. This represents the third consecutive annual double-digit increase, highlighting the Company's commitment to return cash to shareholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Restructuring Plan** - On February 16, 2023, Dentsply Sirona announced that its Board of Directors has approved an organizational restructuring plan intended to improve operational performance and drive shareholder value creation. The restructuring plan anticipates a reduction in the Company's global workforce of approximately 8% to 10%. The proposed changes are subject to co-determination processes with employee representative groups in countries where required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Dentsply Sirona to attend IDS 2023** - Dentsply Sirona will participate in the 40th International Dental Show (IDS) in Cologne, Germany, which takes place from March 14-18, 2023. The company plans to present interactive events, feature digital experiences, and host live demonstrations at its exhibition space. Held every two years, IDS is the leading trade fair for the dental industry.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **DS World Dubai** - In early February 2023, the first-ever DS World Dubai took place with more than 800 registered attendees from 47 countries. DS World Dubai was the fourth DS World event completed in the last six months, emphasizing Dentsply Sirona's commitment to clinical education, innovation, and the power of collaboration; more than 7,000 dental professionals have engaged through these four events.

![xraylineonly.jpg](xraylineonly.jpg)

------

**Conference Call/Webcast Information**

Dentsply Sirona's management team will host an investor conference call and live webcast on February 28, 2023 at 8:30 am ET. A live webcast of the investor conference call and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.

For those planning to participate on the call, please register at https://register.vevent.com/register/BI56c586b6b5714a6ab9bdab080355052e. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

**About Dentsply Sirona**

Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona's products provide innovative, high-quality and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona's headquarters is located in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

**Contact Information:**

Investors:

Andrea Daley

Vice President, Investor Relations

+1-704-805-1293

InvestorRelations@dentsplysirona.com

Press:

Marion Par-Weixlberger

Vice President, Public Relations & Corporate Communications

+43 676 848414588

marion.par-weixlberger@dentsplysirona.com

![xraylineonly.jpg](xraylineonly.jpg)

------

**<u>Forward-Looking Statements and Associated Risks</u>**

This Press Release contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the expected timing, benefits and costs associated with the Company's restructuring plan described in this Press Release. The Company's forward-looking statements represent current expectations and beliefs and involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements and no assurance can be given that the results described in such forward-looking statements will be achieved. Investors are cautioned not to place undue reliance on such forward-looking statements which speak only as of the date they are made. The forward-looking statements are subject to numerous assumptions, risks and uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. The Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause the Company's actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following: the Company's ability to remain profitable in a very competitive marketplace, which depends upon the Company's ability to differentiate its products and services from those of competitors; the Company's failure to realize assumptions and projections which may result in the need to record additional impairment charges; the effect of changes to the Company's distribution channels for its products and the failure of significant distributors of the Company to effectively manage their inventories; the Company's ability to control costs and failure to realize expected benefits of cost reduction and restructuring efforts and the Company's failure to anticipate and appropriately adapt to changes or trends within the rapidly changing dental industry. Furthermore, many of these risks and uncertainties are currently amplified by and may continue to be amplified by or may, in the future, be amplified by, the COVID-19 pandemic and the impact of varying private and governmental responses that affect our customers, employees, vendors and the economies and communities where they operate. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, ("Risk Factors") in the Company's most recent Form 10-K, including any amendments thereto, and any updating information which may be contained in the Company's other filings with the SEC, when reviewing any forward-looking statement. The Company notes these factors for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either the foregoing lists, or the risks identified in the Company's SEC filings, to be a complete discussion of all potential risks or uncertainties.

![xraylineonly.jpg](xraylineonly.jpg)

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **DENTSPLY SIRONA INC. AND SUBSIDIARIES** | **DENTSPLY SIRONA INC. AND SUBSIDIARIES** | **DENTSPLY SIRONA INC. AND SUBSIDIARIES** | **DENTSPLY SIRONA INC. AND SUBSIDIARIES** | **DENTSPLY SIRONA INC. AND SUBSIDIARIES** |
| **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** | **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** | **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** | **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** | **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** |
| (In millions, except per share amounts and percentages) | (In millions, except per share amounts and percentages) | (In millions, except per share amounts and percentages) | (In millions, except per share amounts and percentages) | (In millions, except per share amounts and percentages) |
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | (unaudited) |
|  | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Net sales | $983 | $1103 | $3922 | $4231 |
| Cost of products sold | 466 | 499 | 1795 | 1884 |
| Gross profit | 517 | 604 | 2127 | 2347 |
| Selling, general, and administrative expenses | 402 | 377 | 1589 | 1551 |
| Research and development expenses | 43 | 49 | 174 | 171 |
| Goodwill impairment |  |  | 1187 |  |
| Intangible asset impairment and other costs | 7 | 6 | 114 | 17 |
| Operating (loss) income | 65 | 172 | (937) | 608 |
| Other income and expenses: |  |  |  |  |
| &nbsp;&nbsp;Interest expense, net | 19 | 12 | 60 | 55 |
| &nbsp;&nbsp;Other expense (income), net | 38 | 4 | 58 | 8 |
| (Loss) income before income taxes | 8 | 156 | (1055) | 545 |
| (Benefit) provision for income taxes | 23 | 37 | (105) | 134 |
| Net (loss) income | (15) | 119 | (950) | 411 |
| &nbsp;&nbsp;Less: Net income (loss) attributable to noncontrolling interests |  |  |  |  |
| Net (loss) income attributable to Dentsply Sirona | $(15) | $119 | $(950) | $411 |
| Net (loss) income per common share attributable to Dentsply Sirona: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.07) | $0.55 | $(4.41) | $1.88 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.07) | $0.54 | $(4.41) | $1.87 |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 215.1 | 218.0 | 215.5 | 218.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 215.1 | 219.2 | 215.5 | 220.2 |

---

![xraylineonly.jpg](xraylineonly.jpg)

------

---

| | | |
|:---|:---|:---|
| **DENTSPLY SIRONA INC. AND SUBSIDIARIES** | **DENTSPLY SIRONA INC. AND SUBSIDIARIES** | **DENTSPLY SIRONA INC. AND SUBSIDIARIES** |
| **CONDENSED CONSOLIDATED BALANCE SHEETS** | **CONDENSED CONSOLIDATED BALANCE SHEETS** | **CONDENSED CONSOLIDATED BALANCE SHEETS** |
| (In millions) | (In millions) | (In millions) |
| (unaudited) | (unaudited) | (unaudited) |
|  | **December 31, 2022** | **December 31, 2021** |
| **Assets** |  |  |
| &nbsp;&nbsp;Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $365 | $339 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable-trade, net | 632 | 750 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 627 | 515 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 269 | 248 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 1893 | 1852 |
| &nbsp;&nbsp;Property, plant and equipment, net | 761 | 773 |
| &nbsp;&nbsp;Operating lease right-of-use assets, net | 200 | 198 |
| &nbsp;&nbsp;Identifiable intangible assets, net | 1903 | 2319 |
| &nbsp;&nbsp;Goodwill, net | 2688 | 3976 |
| &nbsp;&nbsp;Other noncurrent assets | 198 | 121 |
| Total Assets | $7643 | $9239 |
| **Liabilities and Equity** |  |  |
| &nbsp;&nbsp;Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $279 | $262 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 727 | 760 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 46 | 57 |
| &nbsp;&nbsp;&nbsp;&nbsp;Notes payable and current portion of long-term debt | 118 | 182 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 1170 | 1261 |
| &nbsp;&nbsp;Long-term debt | 1826 | 1913 |
| &nbsp;&nbsp;Operating lease liabilities | 149 | 149 |
| &nbsp;&nbsp;Deferred income taxes | 287 | 391 |
| &nbsp;&nbsp;Other noncurrent liabilities | 399 | 528 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities | 3831 | 4242 |
| &nbsp;&nbsp;Total Equity | 3812 | 4997 |
| **Total Liabilities and Equity** | $7643 | $9239 |

---

![xraylineonly.jpg](xraylineonly.jpg)

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(In millions)

(unaudited)

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** |
| **Cash flows from operating activities:** |  |  |
| Net (loss) income | $(950) | $411 |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 119 | 124 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 209 | 222 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | 1187 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Indefinite-lived intangible asset impairment | 100 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (228) | (25) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock based compensation expense | 59 | 48 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity in earnings from unconsolidated affiliates | 36 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-cash (income) expense | 60 | 24 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on sale or disposal of non-strategic businesses and product lines | 3 | (14) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities, net of acquisitions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable-trade, net | 85 | (117) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | (141) | (64) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets, net | (33) | (32) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other noncurrent assets | 1 | (10) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 30 | (49) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | (6) | 100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | (15) | 17 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other noncurrent liabilities | 1 | 12 |
| **Net cash provided by operating activities** | $517 | $657 |
| **Cash flows from investing activities:** |  |  |
| Cash paid for acquisitions of businesses and equity investments, net of cash acquired |  | (248) |
| Cash received on sale of non-strategic businesses or product lines |  | 28 |
| Capital expenditures | (149) | (142) |
| Cash received on derivative contracts | 13 | 2 |
| Other investing activities, net | (2) | 2 |
| **Net cash used in investing activities** | $(138) | $(358) |
| **Cash flows from financing activities:** |  |  |
| Proceeds from long-term borrowings, net of deferred financing costs | 6 | 16 |
| Repayments on long-term borrowings | (2) | (297) |
| Net borrowings (repayments) on short-term borrowings | (64) | 179 |
| Proceeds from exercised stock options | 6 | 51 |
| Cash paid for treasury stock | (150) | (200) |
| Cash dividends paid | (104) | (92) |
| Other financing activities, net | (21) | (36) |
| **Net cash (used in) provided by financing activities** | $(329) | $(379) |
| **Effect of exchange rate changes on cash and cash equivalents** | (24) | (19) |
| **Net increase (decrease) in cash and cash equivalents** | 26 | (99) |
| **Cash and cash equivalents at beginning of period** | 339 | 438 |
| **Cash and cash equivalents at end of period** | $365 | $339 |
| Supplemental disclosures of cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest paid, net of amounts capitalized | $70 | $64 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes paid, net of refunds | 122 | 148 |
| Non-cash investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in accounts payable related to capital expenditures | $(6) | $19 |

---

![xraylineonly.jpg](xraylineonly.jpg)

------

**<u>Non-GAAP Financial Measures</u>**

In addition to results determined in accordance with U.S. generally accepted accounting principles ("US GAAP") the Company provides certain measures in this press release, described below, which are not calculated in accordance with US GAAP and therefore represent Non-GAAP measures. These Non-GAAP measures may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies.

Management believes that these Non-GAAP measures are helpful as they provide another measure of the results of operations, and are frequently used by investors and analysts to evaluate the Company's performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company.

<u>Organic Sales</u>

The Company defines "organic sales" as the reported net sales adjusted for: (1) net sales from acquired businesses recorded prior to the first anniversary of the acquisition, (2) net sales attributable to disposed businesses or discontinued product lines in both the current and prior year periods, and (3) the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates.

<u>Adjusted Operating Income (Loss) and Margin</u>

Adjusted operating income (loss) is computed by excluding the following items from operating income:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Business combination related costs and fair value adjustments. These adjustments include costs related to consummating and integrating acquired businesses, as well as net gains and losses related to the disposed businesses. In addition, this category includes the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below. Although the Company is regularly engaged in activities to find and act on opportunities for strategic growth and enhancement of product offerings, the costs associated with these activities may vary significantly between periods based on the timing, size and complexity of acquisitions and as such may not be indicative of past and future performance of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Impairment related charges and other costs. These adjustments include charges related to goodwill and intangible asset impairments. Other costs include costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, lease and contract termination costs, and related professional service costs associated with specific restructuring initiatives. The Company is continually seeking to take actions that could enhance its efficiency; consequently restructuring charges may recur but are subject to significant fluctuations from period to period due to the varying levels of restructuring activity, and as such may not be indicative of past and future performance of the Company. Other costs also include legal settlements, executive separation costs, and changes in accounting principle recorded within the period. Beginning in the second quarter of 2022, this category includes costs related to the recent investigation and associated remediation activities which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.

![xraylineonly.jpg](xraylineonly.jpg)

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Amortization of purchased intangible assets. This adjustment excludes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value in purchase accounting. Although these costs contribute to revenue generation and will recur in future periods, their amounts are significantly impacted by the timing and size of acquisitions, and as such may not be indicative of the future performance of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) Fair value and credit risk adjustments. These adjustments include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, and equity-method investments. Although these adjustments are recurring in nature, they are subject to significant fluctuations from period to period due to changes in the underlying assumptions and market conditions. The non-service component of pension expense is a recurring item, however it is subject to significant fluctuations from period to period due to changes in actuarial assumptions, interest rates, plan changes, settlements, curtailments, and other changes in facts and circumstances. As such, these items may not be indicative of past and future performance of the Company.

Adjusted operating margin is calculated by dividing adjusted operating income by net sales.

<u>Adjusted Net Income (Loss)</u>

Adjusted net income (loss) consists of the reported net income (loss) in accordance with US GAAP, adjusted to exclude the items identified above, the related income tax impacts, and discrete income tax adjustments such as: final settlement of income tax audits, discrete tax items resulting from the implementation of restructuring initiatives and the vesting and exercise of employee share-based compensation, any difference between the interim and annual effective tax rate, and adjustments relating to prior periods.

These adjustments are irregular in timing, and the variability in amounts may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

<u>Adjusted Earnings (Loss) Per Diluted Share</u>

Adjusted earnings (loss) (EPS) per diluted share is computed by dividing adjusted earnings (losses) attributable to Dentsply Sirona shareholders by the diluted weighted average number of common shares outstanding.

<u>Adjusted EBITDA</u>

Adjusted EBITDA is computed by excluding interest, income tax expense, depreciation and amortization, as well as the adjustments described above for computing Adjusted Operating Income.

<u>Adjusted Free Cash Flow Conversion</u>

The Company defines adjusted free cash flow as net cash provided by operating activities minus capital expenditures during the same period, and adjusted free cash flow conversion is defined as that number divided by adjusted net income (loss). Management believes that this Non-GAAP measure is important for use in evaluating the Company's financial performance as it measures our ability to efficiently generate cash from our business operations relative to earnings. It should be considered in addition to, rather than as a substitute for, net income as a measure of our performance or net cash provided by operating activities as a measure of our liquidity.

![xraylineonly.jpg](xraylineonly.jpg)

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except percentages)

(unaudited)

A reconciliation of reported net sales to organic sales by geographic region is as follows:

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Q4 2022 Change** | **Q4 2022 Change** | **Q4 2022 Change** | **Q4 2022 Change** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** |
| (in millions, except percentages) | **US** | **Europe** | **ROW** | **Total** | **US** | **Europe** | **ROW** | **Total** | **US** | **Europe** | **ROW** | **Total** |
| **Net sales** | $369 | $376 | $238 | $983 | (3.9%) | (14.1%) | (15.7%) | (10.9%) | $386 | $436 | $281 | $1103 |
| Foreign exchange impact |  |  |  |  | (2.2%) | (10.9%) | (12.7%) | (8.3%) |  |  |  |  |
| **Organic sales** |  |  |  |  | (1.7%) | (3.2%) | (3.0%) | (2.6%) |  |  |  |  |

---

Percentages are based on actual values and may not recalculate due to rounding.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **2022 Change** | **2022 Change** | **2022 Change** | **2022 Change** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** |
| (in millions, except percentages) | **US** | **Europe** | **ROW** | **Total** | **US** | **Europe** | **ROW** | **Total** | **US** | **Europe** | **ROW** | **Total** |
| **Net sales** | $1392 | $1559 | $971 | $3922 | (5.9%) | (6.9%) | (9.8%) | (7.3%) | $1480 | $1675 | $1076 | $4231 |
| Foreign exchange impact |  |  |  |  | (1.4%) | (9.8%) | (9.6%) | (6.8%) |  |  |  |  |
| Acquisitions |  |  |  |  | 0.2% | —% | —% | 0.1% |  |  |  |  |
| Divestitures and discontinued products |  |  |  |  | (0.1%) | (0.1%) | (0.1%) | (0.1%) |  |  |  |  |
| **Organic sales** |  |  |  |  | (4.6%) | 3.0% | (0.1%) | (0.5%) |  |  |  |  |

---

Percentages are based on actual values and may not recalculate due to rounding.

A reconciliation of reported net sales to organic sales by segment is as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Q4 2022 Change** | **Q4 2022 Change** | **Q4 2022 Change** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** |
| (in millions, except percentages) | Technologies & Equipment | Consumables | Total | Technologies & Equipment | Consumables | Total | Technologies & Equipment | Consumables | Total |
| **Net sales** | $602 | $381 | $983 | (11.6%) | (9.9%) | (10.9%) | $680 | $423 | $1103 |
| Foreign exchange impact |  |  |  | (9.4%) | (6.5%) | (8.3%) |  |  |  |
| **Organic sales** |  |  |  | (2.2%) | (3.4%) | (2.6%) |  |  |  |

---

Percentages are based on actual values and may not recalculate due to rounding.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **2022 Change** | **2022 Change** | **2022 Change** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** |
| (in millions, except percentages) | Technologies & Equipment | Consumables | Total | Technologies & Equipment | Consumables | Total | Technologies & Equipment | Consumables | Total |
| **Net sales** | $2318 | $1604 | $3922 | (7.4%) | (7.1%) | (7.3%) | $2504 | $1727 | $4231 |
| Foreign exchange impact |  |  |  | (7.9%) | (5.2%) | (6.8%) |  |  |  |
| Acquisitions |  |  |  | 0.1% | —% | 0.1% |  |  |  |
| Divestitures and discontinued products |  |  |  | —% | (0.2%) | (0.1%) |  |  |  |
| **Organic sales** |  |  |  | 0.4% | (1.7%) | (0.5%) |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;Percentages are based on actual values and may not recalculate due to rounding.

![xraylineonly.jpg](xraylineonly.jpg)

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except per share amounts and percentages)

(unaudited)

For the three months ended December 31, 2022, a reconciliation of select items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **GAAP** | | | | | | | | **ADJUSTED NON-GAAP** |
| (in millions, except per share amounts and percentages) | **Three Months Ended December 31, 2022** | **Amortization of Purchased Intangible Assets** | **Impairment Related Charges and Other Costs (a)** | **Business Combination Related Costs and Fair Value Adjustments** | **Fair Value and Credit Risk Adjustments** | **Tax Impact of Non-GAAP Adjustments** | **Income Tax Related Adjustments** | **Total Non-GAAP Adjustments** | **Three Months Ended December 31, 2022** |
| NET SALES | $983 |  |  |  |  |  |  | $— | $983 |
| GROSS PROFIT | 517 | 29 | 6 |  |  |  |  | 35 | 552 |
| *% OF NET SALES* | *52.6 %* |  |  |  |  |  |  |  | *56.2 %* |
| SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES | 402 | (21) | (23) | (3) |  |  |  | (47) | 355 |
| *% OF NET SALES* | *40.9 %* |  |  |  |  |  |  |  | *36.1 %* |
| RESEARCH AND DEVELOPMENT EXPENSES | 43 |  |  |  |  |  |  |  | 43 |
| INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS | 7 |  | (7) |  |  |  |  | (7) |  |
| OPERATING INCOME | 65 | 50 | 36 | 3 |  |  |  | 89 | 154 |
| % OF NET SALES | *6.6 %* |  |  |  |  |  |  |  | *15.7 %* |
| OTHER INCOME AND EXPENSE | 57 |  |  | (3) | (23) |  |  | (26) | 31 |
| INCOME BEFORE INCOME TAXES | 8 | 50 | 36 | 6 | 23 |  |  | 115 | 123 |
| PROVISION FOR INCOME TAXES | 23 |  |  |  |  | 23 | (22) | 1 | 24 |
| % OF PRE-TAX INCOME | *278.7 %* |  |  |  |  |  |  |  | *19.7 %* |
| LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS |  |  |  |  |  |  |  |  |  |
| NET INCOME ATTRIBUTABLE TO DENTSPLY SIRONA | $(15) |  |  |  |  |  |  | $114 | $99 |
| % OF NET SALES | *(1.6) %* |  |  |  |  |  |  |  | *10.1 %* |
| EARNINGS PER SHARE - DILUTED | $(0.07) |  |  |  |  |  |  | $0.53 | $0.46 |
| Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share |  |  |  |  |  |  | $215.1 |
| Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share |  |  |  |  |  |  | $215.5 |

---

Percentages are based on actual values and may not recalculate due to rounding.

(a) Other Costs includes $16 million in costs related to the internal investigation comprised of $12 million in professional service fees, and $4 million in turnover and other employee related SG&A expenses.

For the three months ended December 31, 2022, the following table presents the details of the "Impairment Related Charges and Other Costs" column in the above table and the affected line item in the Consolidated Statements of Operations:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| (in millions) | Impairments | Costs Related to Restructuring Plans | Professional Services Costs | Incentive Compensation | Other | Total |
| Cost of products sold | $— | $— | $— | $— | $6 | $6 |
| Selling, general, and administrative expenses |  | 1 | 18 | 4 |  | 23 |
| Intangible asset impairment and other costs | 6 | 1 |  |  |  | 7 |
| Total | $6 | $2 | $18 | $4 | $6 | $36 |

---

![xraylineonly.jpg](xraylineonly.jpg)

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except per share amounts and percentages)

(unaudited)

For the three months ended December 31, 2021, a reconciliation of select items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **GAAP** | | | | | | | | **ADJUSTED NON-GAAP** |
| (in millions, except per share amounts and percentages) | **Three Months Ended December 31, 2021** | **Amortization of Purchased Intangible Assets** | **Impairment Related Charges and Other Costs (a)** | **Business Combination Related Costs and Fair Value Adjustments** | **Fair Value and Credit Risk Adjustments** | **Tax Impact of Non-GAAP Adjustments** | **Income Tax Related Adjustments** | **Total Non-GAAP Adjustments** | **Three Months Ended December 31, 2021** |
| NET SALES | $1103 |  |  |  |  |  |  | $— | $1103 |
| GROSS PROFIT | 604 | 33 |  | 1 |  |  |  | 34 | 638 |
| *% OF NET SALES* | *54.7%* |  |  |  |  |  |  |  | *57.8%* |
| SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES | 377 | (23) |  |  |  |  |  | (23) | 354 |
| *% OF NET SALES* | *33.3%* |  |  |  |  |  |  |  | *32.1%* |
| RESEARCH AND DEVELOPMENT EXPENSES | 49 |  |  |  |  |  |  |  | 49 |
| INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS | 6 |  | (6) |  |  |  |  | (6) |  |
| OPERATING INCOME | 172 | 56 | 6 | 1 |  |  |  | 63 | 235 |
| *% OF NET SALES* | *15.6%* |  |  |  |  |  |  |  | *21.3%* |
| OTHER INCOME AND EXPENSE | 16 |  |  | 1 | (14) |  |  | (13) | 3 |
| INCOME BEFORE INCOME TAXES | 156 | 56 | 6 |  | 14 |  |  | 76 | 232 |
| PROVISION FOR INCOME TAXES | 37 |  |  |  |  | 19 | (5) | 14 | 51 |
| *% OF PRE-TAX INCOME* | *23.7%* |  |  |  |  |  |  |  | *21.8%* |
| LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS |  |  |  |  |  |  |  |  |  |
| NET INCOME ATTRIBUTABLE TO DENTSPLY SIRONA | $119 |  |  |  |  |  |  | $62 | $181 |
| *% OF NET SALES* | *10.8%* |  |  |  |  |  |  |  | *16.4 %* |
| EARNINGS PER SHARE - DILUTED | $0.54 |  |  |  |  |  |  | $0.29 | $0.83 |

---

Percentages are based on actual values and may not recalculate due to rounding.

For the three months ended December 31, 2021, the following table presents the details of the "Impairment Related Charges and Other Costs" column in the above table and the affected line item in the Consolidated Statements of Operations:

---

| | | | |
|:---|:---|:---|:---|
| (in millions) | Costs Related to Restructuring Plans | Other | Total |
| Intangible asset impairment and other costs | $5 | $1 | $6 |
| Total | $5 | $1 | $6 |

---

![xraylineonly.jpg](xraylineonly.jpg)

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except per share amounts and percentages)

(unaudited)

For the year ended December 31, 2022, a reconciliation of select items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **GAAP** | | | | | | | | **ADJUSTED NON-GAAP** |
| (in millions, except per share amounts and percentages) | **Twelve Months Ended December 31, 2022** | **Amortization of Purchased Intangible Assets** | **Impairment Related Charges and Other Costs (a)** | **Business Combination Related Costs and Fair Value Adjustments** | **Fair Value and Credit Risk Adjustments** | **Tax Impact of Non-GAAP Adjustments** | **Income Tax Related Adjustments** | **Total Non-GAAP Adjustments** | **Twelve Months Ended December 31, 2022** |
| NET SALES | $3922 |  |  |  |  |  |  | $— | $3922 |
| GROSS PROFIT | 2127 | 121 | 7 | 1 |  |  |  | 129 | 2256 |
| *% OF NET SALES* | *54.2%* |  |  |  |  |  |  |  | *57.5%* |
| SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES | 1589 | (88) | (70) | (5) |  |  |  | (163) | 1426 |
| *% OF NET SALES* | *40.5%* |  |  |  |  |  |  |  | *36.4%* |
| RESEARCH AND DEVELOPMENT EXPENSES | 174 |  | (1) |  |  |  |  | (1) | 173 |
| GOODWILL IMPAIRMENT | 1187 |  | (1187) |  |  |  |  | (1187) |  |
| INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS | 114 |  | (114) |  |  |  |  | (114) |  |
| OPERATING (LOSS) INCOME | (937) | 209 | 1379 | 6 |  |  |  | 1594 | 657 |
| *% OF NET SALES* | *(23.9%)* |  |  |  |  |  |  |  | *16.8%* |
| OTHER INCOME AND EXPENSE | 118 |  |  | (3) | (43) |  |  | (46) | 72 |
| (LOSS) INCOME BEFORE INCOME TAXES | (1055) | 209 | 1379 | 9 | 43 |  |  | 1640 | 585 |
| (BENEFIT) PROVISION FOR INCOME TAXES | (105) |  |  |  |  | 271 | (33) | 238 | 133 |
| *% OF PRE-TAX INCOME* | *9.9%* |  |  |  |  |  |  |  | *22.7%* |
| LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS |  |  |  |  |  |  |  |  |  |
| NET (LOSS) INCOME ATTRIBUTABLE TO DENTSPLY SIRONA | $(950) |  |  |  |  |  |  | $1402 | $452 |
| *% OF NET SALES* | *(24.2%)* |  |  |  |  |  |  |  | *11.5 %* |
| (LOSS) EARNINGS PER SHARE - DILUTED | $(4.41) |  |  |  |  |  |  | $6.50 | $2.09 |
| Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share | Shares used in calculating diluted US GAAP net loss per share |  | 215.5 |
| Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share | Shares used in calculating diluted non-US GAAP net income per share |  | 215.9 |

---

Percentages are based on actual values and may not recalculate due to rounding.

(a) Other Costs includes $61 million in costs related to the internal investigation comprised of $31 million in professional service fees, and $30 million in turnover and other employee related SG&A expenses.

For the year ended December 31, 2022, the following table presents the details of the "Impairment Related Charges and Other Costs" column in the above table and the affected line item in the Consolidated Statements of Operations:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| (in millions) | Impairments | Severance Costs Related to Executives | Costs Related to Restructuring Plans | Professional Services Costs | Incentive Compensation | Other | Total |
| Cost of products sold | $— | $— | $— | $— | $1 | $6 | $7 |
| Selling, general, and administrative expenses |  | 18 |  | 39 | 11 | 2 | 70 |
| Goodwill impairment | 1187 |  |  |  |  |  | 1187 |
| Research and Development |  |  |  |  |  | 1 | 1 |
| Intangible asset impairment and other costs | 100 |  | 13 |  |  | 1 | 114 |
| Total | $1287 | $18 | $13 | $39 | $12 | $10 | $1379 |

---

![xraylineonly.jpg](xraylineonly.jpg)

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except per share amounts and percentages)

(unaudited)

For the year ended December 31, 2021, a reconciliation of select items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **GAAP** | | | | | | | | **ADJUSTED NON-GAAP** |
| (in millions, except per share amounts and percentages) | **Twelve Months Ended December 31, 2021** | **Amortization of Purchased Intangible Assets** | **Impairment Related Charges and Other Costs (a)** | **Business Combination Related Costs and Fair Value Adjustments** | **Fair Value and Credit Risk Adjustments** | **Tax Impact of Non-GAAP Adjustments** | **Income Tax Related Adjustments** | **Total Non-GAAP Adjustments** | **Twelve Months Ended December 31, 2021** |
| NET SALES | $4231 |  |  |  |  |  |  | $— | $4231 |
| GROSS PROFIT | 2347 | 131 | (6) | 3 |  |  |  | 128 | 2475 |
| *% OF NET SALES* | *55.5%* |  |  |  |  |  |  |  | *58.5%* |
| SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES | 1551 | (91) | (3) | (11) |  |  |  | (105) | 1446 |
| *% OF NET SALES* | *36.6%* |  |  |  |  |  |  |  | *34.2%* |
| RESEARCH AND DEVELOPMENT EXPENSES | 171 |  |  |  |  |  |  |  | 171 |
| INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS | 17 |  | (17) |  |  |  |  | (17) |  |
| OPERATING INCOME | 608 | 222 | 14 | 14 |  |  |  | 250 | 858 |
| *% OF NET SALES* | *14.4%* |  |  |  |  |  |  |  | *20.3%* |
| OTHER INCOME AND EXPENSE | 63 |  |  | 11 | (21) |  |  | (10) | 53 |
| INCOME BEFORE INCOME TAXES | 545 | 222 | 14 | 3 | 21 |  |  | 260 | 805 |
| PROVISION FOR INCOME TAXES | 134 |  |  |  |  | 65 | (15) | 50 | 184 |
| *% OF PRE-TAX INCOME* | *24.6%* |  |  |  |  |  |  |  | *22.9%* |
| LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS |  |  |  |  |  |  |  |  |  |
| NET INCOME ATTRIBUTABLE TO DENTSPLY SIRONA | $411 |  |  |  |  |  |  | $210 | $621 |
| % OF NET SALES | *9.7%* |  |  |  |  |  |  |  | *14.7 %* |
| EARNINGS PER SHARE - DILUTED | $1.87 |  |  |  |  |  |  | $0.95 | $2.82 |

---

Percentages are based on actual values and may not recalculate due to rounding.

For the year ended December 31, 2021, the following table presents the details of the "Impairment Related Charges and Other Costs" column in the above table and the affected line item in the Consolidated Statements of Operations:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| (in millions) | Severance Costs Related to Executives | Costs Related to Restructuring Plans | Professional Services Costs | Other | Total |
| Cost of products sold | $— | $(3) | $— | $(3) | $(6) |
| Selling, general, and administrative expenses | (1) | 1 | 2 | 1 | 3 |
| Intangible asset impairment and other costs |  | 21 |  | (4) | 17 |
| Total | $(1) | $19 | $2 | $(6) | $14 |

---

![xraylineonly.jpg](xraylineonly.jpg)

------

A reconciliation of as reported GAAP net income to Adjusted EBITDA for the three ended December 31, 2022 and 2021 is as follows:

---

| | | |
|:---|:---|:---|
| (in millions) | 2022 | 2021 |
| **GAAP net (loss) income** | $(15) | $119 |
| &nbsp;&nbsp;Interest expense, net | 19 | 12 |
| &nbsp;&nbsp;Income tax expense | 23 | 37 |
| &nbsp;&nbsp;Depreciation<sup>(1)</sup> | 28 | 29 |
| &nbsp;&nbsp;Amortization of purchased intangible assets | 50 | 56 |
| &nbsp;&nbsp;Impairment related costs and other costs | 36 | 6 |
| &nbsp;&nbsp;Business combination related costs and fair value adjustments | 6 |  |
| &nbsp;&nbsp;Fair value and credit risk adjustments | 23 | 14 |
| **Adjusted EBITDA** | $170 | $273 |

---

(1) Excludes those depreciation related amounts which were included as part of the business combination related adjustments below.

A reconciliation of as reported GAAP net income to Adjusted EBITDA for the year ended December 31, 2022 and 2021 is as follows:

---

| | | |
|:---|:---|:---|
| (in millions) | 2022 | 2021 |
| **GAAP net (loss) income** | $(950) | $411 |
| &nbsp;&nbsp;Interest expense, net | 60 | 55 |
| &nbsp;&nbsp;Income tax expense | (105) | 134 |
| &nbsp;&nbsp;Depreciation<sup>(1)</sup> | 116 | 118 |
| &nbsp;&nbsp;Amortization of purchased intangible assets | 209 | 222 |
| &nbsp;&nbsp;Impairment related costs and other costs | 1379 | 14 |
| &nbsp;&nbsp;Business combination related costs and fair value adjustments | 9 | 3 |
| &nbsp;&nbsp;Fair value and credit risk adjustments | 43 | 21 |
| **Adjusted EBITDA** | $761 | $978 |

---

(1) Excludes those depreciation related amounts which were included as part of the business combination related adjustments below.

A reconciliation of adjusted free cash flow conversion for the three months ended December 31, 2022 and 2021 is as follows:

---

| | | |
|:---|:---|:---|
| (in millions, except percentages) | 2022 | 2021 |
| Net cash provided by operating activities | $142 | $222 |
| Capital Expenditures | (32) | (41) |
| Adjusted free cash flow | 110 | 181 |
| Adjusted net income | $99 | $181 |
| **Adjusted free cash flow conversion** | 110% | 100% |

---

![xraylineonly.jpg](xraylineonly.jpg)

------

A reconciliation of adjusted free cash flow conversion for the year ended December 31, 2022 and 2021 is as follows:

---

| | | |
|:---|:---|:---|
| (in millions, except percentages) | 2022 | 2021 |
| Net cash provided by operating activities | $517 | $657 |
| Capital Expenditures | (149) | (142) |
| Adjusted free cash flow | 368 | 515 |
| Adjusted net income | $452 | $621 |
| **Adjusted free cash flow conversion** | 81% | 83% |

---

![xraylineonly.jpg](xraylineonly.jpg)